GnRH agonists: an alternative to surgery?
Maheux
R
R
Department of Obstetrics and Gynecology, Université Laval, Québec, Canada.
D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects / Q000502:physiology; D004359:Drug Therapy, Combination; D004958:Estradiol / Q000097:blood / Q000378:metabolism; D015914:Estrogen Replacement Therapy; D005260:Female; D005500:Follow-Up Studies; D017273:Goserelin / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy* / Q000601:surgery; D050356:Lipid Metabolism; D008055:Lipids / Q000097:blood; D008875:Middle Aged; D013997:Time Factors; D014592:Uterine Hemorrhage / Q000503:physiopathology; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000601:surgery
D018931:Antineoplastic Agents, Hormonal; D008055:Lipids; D017273:Goserelin; D004958:Estradiol